07/11/2025
5:02 AM | Inozyme Pharma (Filer)
| Form 15-12G | |
07/03/2025
6:16 PM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
5:59 PM | Hopfner Robert Lorne (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:03 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:04 PM | Inozyme Pharma (Issuer)
Sullivan Lynne Marie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:07 PM | Bolte Axel (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:08 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2025
11:15 PM | Inozyme Pharma (Filer)
| Form EFFECT | |
07/01/2025
11:15 PM | Inozyme Pharma (Filer)
| Form EFFECT | |
07/01/2025
8:29 AM | Inozyme Pharma (Filer)
| Form POS AM | |
07/01/2025
8:43 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
Get the Latest News and Ratings for INZY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. |
07/01/2025
8:44 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:45 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:48 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:49 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:51 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:54 AM | Inozyme Pharma (Subject)
Nasdaq Stock Market LLC (Filed by)
| Form 25-NSE | |
07/01/2025
8:18 AM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T/A | |
07/01/2025
8:21 AM | Inozyme Pharma (Subject)
| Form SC 14D9/A | |
07/01/2025
8:25 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/01/2025
8:27 AM | Inozyme Pharma (Filer)
| Form POS AM | |
06/20/2025
6:29 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2025
6:31 PM | Inozyme Pharma (Filer)
| Form DEFA14A | |
06/17/2025
6:28 AM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T/A | |
06/17/2025
5:15 AM | Inozyme Pharma (Subject)
| Form SC 14D9/A | |
06/04/2025
4:09 PM | GLAZER CAPITAL, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G | |
06/04/2025
3:51 PM | Inozyme Pharma (Subject)
| Form SC 14D9/A | |
06/04/2025
3:32 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T/A | |
06/02/2025
6:35 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/02/2025
6:14 AM | Inozyme Pharma (Subject)
| Form SC 14D9 | |
06/02/2025
5:25 AM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T | |
05/30/2025
4:24 PM | Affinity Asset Advisors, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G/A | |
05/19/2025
8:23 PM | Inozyme Pharma (Subject)
| Form SC14D9C | |
05/19/2025
4:22 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-C | |
05/16/2025
8:44 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-C | |
05/16/2025
4:16 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-C | |
05/16/2025
3:40 PM | Inozyme Pharma (Subject)
| Form SC14D9C | |
05/16/2025
7:06 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:33 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:36 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/23/2025
9:28 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G/A | |
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom (Ad) Obscure Metal More Valuable than Gold and Bitcoin… COMBINED?
This strange "AI Metal" holds the key to the $100 trillion AI boom.
Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world.
And you won't believe what he uncovered. Click here to see the details because this could be the biggest tech story of this decade. |
04/03/2025
3:27 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/02/2025
3:27 PM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/02/2025
3:29 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/17/2025
3:24 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/17/2025
3:25 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/17/2025
3:26 PM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/10/2025
4:17 PM | Inozyme Pharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/10/2025
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/10/2025
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/10/2025
7:32 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/10/2025
7:32 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/14/2025
12:59 PM | Inozyme Pharma (Subject)
SAMLYN CAPITAL, LLC (Filed by)
| Form SCHEDULE 13G/A | |
01/10/2025
7:06 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
11:19 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
11/05/2024
7:33 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/05/2024
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
3:34 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G | |
10/03/2024
7:58 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
7:57 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/06/2024
3:52 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
08/06/2024
3:54 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
